儿童自身免疫性肝病及其实验室诊断进展

doi:10.3969/j.issn.1673-8640.2025.03.003

摘要/Abstract

摘要：

自身免疫性肝病（ALD）是因人体免疫功能紊乱引起的一大类慢性进展性肝组织炎症。近年来，儿童ALD的发病率呈升高趋势。儿童ALD的发病情况、临床特点、实验室诊断等与成人均有一定的差异。文章对常见儿童ALD的分类和特征、实验室诊断现状和进展、尚待解决的问题和遗传易感性进行综述，以期为儿童ALD的临床研究和疾病诊治提供参考。

关键词: 自身免疫性肝病, 儿童, 实验室诊断

Abstract:

Autoimmune liver diseases（ALD） is a group of chronic progressive inflammation of liver caused by immune dysfunction. In the recent years，the incidence of ALD in children has risen significantly. The occurrence，clinical characteristics and laboratory diagnosis of ALD in children differ notably from those in adults. This review focuses on the classification and characteristics of common ALD in children，the status and development in laboratory diagnosis，unresolved challenges and genetic susceptibility. The aim is to provide a reference for clinical research and to improve the diagnosis and treatment of ALD in children.

Key words: Autoimmune liver disease, Children, Clinical laboratory diagnosis

中图分类号:

R446.62

马展, 翁文浩. 儿童自身免疫性肝病及其实验室诊断进展[J]. 检验医学, 2025, 40(3): 218-222.

MA Zhan, WENG Wenhao. Autoimmune liver disease in children and progress of laboratory diagnosis[J]. Laboratory Medicine, 2025, 40(3): 218-222.

参考文献 38

[1]	MIELI-VERGANI G, VERGANI D. Autoimmune liver disease in Asian children[J]. Hepatol Int, 2015, 9(2):157-160.
[2]	LEE W S, LUM S H, LIM C B, et al. Characteristics and outcome of autoimmune liver disease in Asian children[J]. Hepatol Int, 2015, 9(2):292-302. DOI PMID
[3]	MAGGIORE G, BERNARD O, MOSCA A, et al. Long-term outcomes of patients with type 1 or 2 autoimmune hepatitis presenting in childhood[J]. J Hepatol, 2023, 78(5):979-988.
[4]	MIELI-VERGANI G, VERGANI D. Autoimmune liver diseases in children - what is different from adulthood?[J]. Best Pract Res Clin Gastroenterol, 2011, 25(6):783-795.
[5]	MACK C L, ADAMS D, ASSIS D N, et al. Diagnosis and management of autoimmune hepatitis in adults and children:2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2):671-722.
[6]	GREGORIO G V, PORTMANN B, REID F, et al. Autoimmune hepatitis in childhood:a 20-year experience[J]. Hepatology, 1997, 25(3):541-547.
[7]	NASTASIO S, MOSCA A, ALTERIO T, et al. Juvenile autoimmune hepatitis:recent advances in diagnosis,management and long-term outcome[J]. Diagnostics(Basel), 2023, 13(17):2753.
[8]	AYDEMIR Y, AKCOREN Z, DEMIR H, et al. Clinical and histopathological features of immunoglobulin G4-associated autoimmune hepatitis in children[J]. J Gastroenterol Hepatol, 2019, 34(4):742-746.
[9]	MAGGIORE G, SOCIE G, SCIVERES M, et al. Seronegative autoimmune hepatitis in children:spectrum of disorders[J]. Dig Liver Dis, 2016, 48(7):785-791.
[10]	ISLEK A, KESKIN H. Seronegative autoimmune hepatitis in children:a single-center experience[J]. Acta Gastroenterol Belg, 2021, 84(2):305-310.
[11]	KHEDR M A, SALEM T A, BOGHDADI G M, et al. Seronegative autoimmune hepatitis in children:a real diagnostic challenge[J]. Wien Klin Wochenschr, 2022, 134(5-6):195-201.
[12]	KAPLAN G G, LAUPLAND K B, BUTZNER D, et al. The burden of large and small duct primary sclerosing cholangitis in adults and children:a population-based analysis[J]. Am J Gastroenterol, 2007, 102(5):1042-1049.
[13]	BOWLUS C L, ARRIVÉ L, BERGQUIST A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma[J]. Hepatology, 2023, 77(2):659-702.
[14]	LIBERAL R, GASPAR R, MACEDO G. Pediatric-onset primary biliary cholangitis[J]. Dig Liver Dis, 2019, 51(7):1064-1065.
[15]	LLEO A, WANG G Q, GERSHWIN M E, et al. Primary biliary cholangitis[J]. Lancet, 2020, 396(10266):1915-1926. DOI PMID
[16]	JULIUSSON G, IMAM M, BJÖRNSSON E S, et al. Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis[J]. Scand J Gastroenterol, 2016, 51(6):745-752.
[17]	GABETA S, NORMAN G L, LIASKOS C, et al. Diagnostic relevance and clinical significance of the new enhanced performance M2(MIT3)ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis[J]. J Clin Immunol, 2007, 27(4):378-387.
[18]	SAITO H, TAKAHASHI A, ABE K, et al. Autoantibodies by line immunoassay in patients with primary biliary cirrhosis[J]. Fukushima J Med Sci, 2012, 58(2):107-116. DOI PMID
[19]	GREGORIO G V, PORTMANN B, KARANI J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood:a 16-year prospective study[J]. Hepatology, 2001, 33(3):544-553.
[20]	倪萍, 凡小丽, 杨丽. 自身免疫性肝病重叠综合征的研究现状[J]. 临床肝胆病杂志, 2020, 36(4):743-748.
[21]	MAU B, HAKAR M, LIN H C, et al. A review of histopathologic features of pediatric autoimmune liver disease[J]. Clin Liver Dis(Hoboken), 2022, 20(4):116-119.
[22]	中国医师协会风湿免疫科医师分会自身抗体检测专业委员会. 抗核抗体检测的临床应用专家共识[J]. 中华检验医学杂志, 2018, 41(4):275-280.
[23]	CHAN E K L, VON MÜHLEN C A, FRITZLER M J, et al. The International Consensus on ANA Patterns(ICAP)in 2021-the 6th workshop and current perspectives[J]. J Appl Lab Med, 2022, 7(1):322-330.
[24]	LIBERAL R, MIELI-VERGANI G, VERGANI D. Clinical significance of autoantibodies in autoimmune hepatitis[J]. J Autoimmun, 2013, 46:17-24 DOI PMID
[25]	MIELI-VERGANI G, VERGANI D, BAUMANN U, et al. Diagnosis and management of pediatric autoimmune liver disease:ESPGHAN hepatology committee position statement[J]. J Pediatr Gastroenterol Nutr, 2018, 66(2):345-360.
[26]	JOHANET C, BALLOT E. Autoantibodies in autoimmune hepatitis:anti-liver kidney microsome type 1(anti-LKM1)and anti-liver cytosol type 1(anti-LC1)antibodies[J]. Clin Res Hepatol Gastroenterol, 2013, 37(2):216-218.
[27]	LEUNG K K, HIRSCHFIELD G M. Autoantibodies in primary biliary cholangitis[J]. Clin Liver Dis, 2022, 26(4):613-627. DOI PMID
[28]	MA D, LIU X, AI G, et al. The etiology and differential diagnosis of "autoimmune hepatitis-like liver disease" in children:a single-center retrospective study[J]. Front Pediatr, 2024, 12:1377333.
[29]	DIESTELHORST J, JUNGE N, JONIGK D, et al. Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis[J]. Sci Rep, 2018, 8(1):419. DOI PMID
[30]	TERZIROLI BERETTA-PICCOLI B, MIELI-VERGANI G, VERGANI D. Autoimmune hepatitis:serum autoantibodies in clinical practice[J]. Clin Rev Allergy Immunol, 2022, 63(2):124-137.
[31]	HARRINGTON C, KRISHNAN S, MACK C L, et al. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis[J]. Hepatology, 2022, 76(6):1862-1879.
[32]	SCIASCIA S, BIZZARO N, MERONI P L, et al. Autoantibodies testing in autoimmunity:diagnostic,prognostic and classification value[J]. Autoimmun Rev, 2023, 22(7):103356.
[33]	OLIANAS A, GUADALUPI G, CABRAS T, et al. Top-down proteomics detection of potential salivary biomarkers for autoimmune liver diseases classification[J]. Int J Mol Sci, 2023, 24(2):959.
[34]	YANG H, CHEN L, LIU Y. A large-scale plasma proteome Mendelian randomization study identifies novel causal plasma proteins related to primary biliary cholangitis[J]. Front Immunol, 2023, 14:1052616.
[35]	ELLINGHAUS D. How genetic risk contributes to autoimmune liver disease[J]. Semin Immunopathol, 2022, 44(4):397-410. DOI PMID
[36]	GERUSSI A, CAPPADONA C, BERNASCONI D P, et al. Improving predictive accuracy in primary biliary cholangitis:a new genetic risk score[J]. Liver Int, 2024, 44(8):1952-1960.
[37]	MACK C L. HLA Associations in pediatric autoimmune liver diseases:current state and future research initiatives[J]. Front Immunol, 2022, 13:1019339.
[38]	GAO W, PENG C, WANG Z, et al. Genetic association and causal relationship between multiple modifiable risk factors and autoimmune liver disease:a two-sample mendelian randomization study[J]. J Transl Med, 2024, 22(1):425.